Papillary renal cell carcinoma

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search
Section editor
Alikhaki.jpg
Ali Raza Khaki, MD
Stanford University
Palo Alto, CA

Social-twitter-icon.png arkhaki

Note: these are regimens tested in histology-specific populations, please see the main RCC page for other regimens.

4 regimens on this page
4 variants on this page


Metastatic disease, first-line

Cabozantinib monotherapy

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Pal et al. 2021 (SWOG S1500) 2016-2019 Randomized Phase II (E-switch-ic) 1. Sunitinib Seems to have superior PFS
2. Crizotinib
3. Savolitinib
Not reported

Note: SWOG S1500 was also open to previously treated patients (maximimum of one line of therapy) but almost all patients were untreated at time of study enrollment.

Targeted therapy

Continued indefinitely

References

  1. SWOG S1500: Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN Jr. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021 Feb 12:S0140-6736(21)00152-5. Epub ahead of print. link to original article contains verified protocol PubMed NCT02761057

Erlotinib monotherapy

back to top

Regimen

Study Years of enrollment Evidence Efficacy
Gordon et al. 2009 (SWOG S0317) 2005-2006 Phase II ORR: 11% (95% CI 3-24%)

Targeted therapy

Continued indefinitely

References

  1. SWOG S0317: Gordon MS, Hussey M, Nagle RB, Lara PN Jr, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009 Dec 1;27(34):5788-93. Epub 2009 Nov 2. link to original article contains verified protocol link to PMC article PubMed NCT00060307

Pembrolizumab monotherapy

back to top

Regimen

Study Years of enrollment Evidence Efficacy
McDermott et al. 2021 (KEYNOTE-427) 2016-NR Phase II ORR: 27%

Note: this reference describes the non-clear cell cohort of KEYNOTE-427.

Immunotherapy

21-day cycle for up to 36 cycles (2 years)

References

  1. KEYNOTE-427: McDermott DF, Lee JL, Ziobro M, Suarez C, Langiewicz P, Matveev VB, Wiechno P, Gafanov RA, Tomczak P, Pouliot F, Donskov F, Alekseev BY, Shin SJ, Bjarnason GA, Castellano D, Silverman RK, Perini RF, Schloss C, Atkins MB. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. J Clin Oncol. 2021 Mar 20;39(9):1029-1039. Epub 2021 Feb 2. link to original article contains protocol PubMed NCT02853344

Sunitinib monotherapy

back to top

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Pal et al. 2021 (SWOG S1500) 2016-2019 Randomized Phase II (C) 1. Cabozantinib Seems to have inferior PFS
2. Crizotinib
3. Savolitinib
Not reported
Choueiri et al. 2020 (SAVOIR) 2017-2018 Phase III (C) Savolitinib Did not meet primary endpoint of PFS

Note: SWOG S1500 was also open to previously treated patients (maximimum of one line of therapy) but almost all patients were untreated at time of study enrollment.

Biomarker eligibility criteria

  • SAVOIR: Chromosome 7 gain, MET amplification, MET kinase domain variations, or HGF amplification without any co-occurring FH or VHL variations

Targeted therapy

42-day cycles

References

  1. Retrospective: Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008 Jan 1;26(1):127-31. link to original article PubMed
  2. SAVOIR: Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, Ottesen LH, Frigault MM, L'Hernault A, Szijgyarto Z, Signoretti S, Albiges L. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Aug 1;6(8):1247-1255. Erratum in: JAMA Oncol. 2020 Sep 1;6(9):1473. link to original article link to PMC article contains verified protocol PubMed NCT03091192
  3. SWOG S1500: Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN Jr. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021 Feb 12:S0140-6736(21)00152-5. Epub ahead of print. link to original article contains verified protocol PubMed NCT02761057